Total | Outcome (%) | Crude OR | (95% CI) | Adjusted OR | (95% CI) | |
---|---|---|---|---|---|---|
1-month survival | ||||||
≤ 20 min | 1084 | 349 (32.2) | Reference | Reference* | ||
21–30 min | 3165 | 190 (6.0) | 0.14 | (0.11–0.16) | 0.25 | (0.20–0.31) |
31–40 min | 5466 | 93 (1.7) | 0.04 | (0.03–0.05) | 0.08 | (0.06–0.10) |
41–60 min | 9378 | 46 (0.5) | 0.01 | (0.01–0.01) | 0.02 | (0.013–0.026) |
61–90 min | 3990 | 8 (0.2) | 0.004 | (0.002–0.009) | 0.005 | (0.003–0.011) |
91–120 min | 708 | 1 (0.1) | 0.003 | (0.000–0.021) | 0.003 | (0.000–0.023) |
P for trend† | < 0.001 | < 0.001 | ||||
Favorable neurological outcome | ||||||
≤ 20 min | 1084 | 226 (20.8) | Reference | Reference* | ||
21–30 min | 3165 | 37 (1.2) | 0.05 | (0.03–0.06) | 0.15 | (0.10–0.23) |
31–40 min | 5466 | 24 (0.4) | 0.02 | (0.011–0.03) | 0.08 | (0.05–0.12) |
41–60 min | 9378 | 12 (0.1) | 0.005 | (0.003–0.009) | 0.02 | (0.01–0.031) |
61–90 min | 3990 | 2 (0.1) | 0.002 | (0.000–0.008) | 0.004 | (0.001–0.016) |
91–120 min | 708 | 0 (0.0) | NA | NA | ||
P for trend† | < 0.001 | < 0.001 |